Analysts questioned whether the complete response letter Replimune received was evidence of changing approval standards at the FDA.

Roche AG’s Genentech unit disclosed outcomes of two studies testing IL-33-targeting astegolimab vs. placebo on top of standard-of-care maintenance therapy in subjects with moderate to very severe ...

The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...

Roche’s IgG2 monoclonal antibody (mAb) astegolimab has yielded mixed results in chronic obstructive pulmonary disease (COPD), ...

Roche announces positive results from pivotal phase IIb ALIENTO & phase III ARNASA trials of astegolimab to treat COPD: Basel Tuesday, July 22, 2025, 13:00 Hrs [IST] Roche announc ...

The fate of IL-33-targeting astegolimab will be determined by talks with regulators, after Roche AG’s Genentech unit rolled out mixed results from a pair of studies testing the compound vs. placebo on ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. SR 14 and SR 142 remain closed in Klickitat County due to the ...

Astegolimab from Roche's Genentech fails phase 3 COPD trial, reflecting challenges in monoclonal antibody treatment for the ...

Swiss pharma giant Roche today reported mixed results from late-stage trials for its experimental drug astegolimab, which is ...

"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...

Basel: Roche has announced topline results from the pivotal phase IIb ALIENTO (n=1,301) and the phase III ARNASA (n=1,375) ...

Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken ...